To amend the Controlled Substances Act to clarify how controlled substance analogues that are imported or offered for import are to be regulated, and for other purposes.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The SIMSA Act of 2025 creates a new "Schedule A" category under the Controlled Substances Act to classify and control synthetic drug analogues that are imported into the U.S. and have chemical structures and effects similar to existing controlled substances. It gives the Attorney General power to temporarily (up to 5 years) or permanently schedule these substances, with input from the Secretary of Health and Human Services.
Who Benefits and How
Law enforcement agencies (DEA, CBP) benefit from clearer legal authority to seize and prosecute synthetic analogues that currently fall through regulatory gaps. The general public benefits from reduced availability of dangerous synthetic drugs like synthetic fentanyl analogues. Legitimate pharmaceutical researchers retain protections through FDA-approved product exemptions and continued research registration pathways.
Who Bears the Burden and How
Illicit synthetic drug importers and manufacturers face up to 20 years imprisonment (30 years for repeat offenders), fines up to million ( million for organizations), and mandatory supervised release. Chemical importers of legitimate Schedule A substances must register with the Attorney General and comply with labeling requirements using IUPAC nomenclature. Pharmaceutical and academic researchers working with newly scheduled substances face new registration and compliance requirements within 30 days of scheduling.
Key Provisions
- Creates Schedule A for imported synthetic analogues with substantially similar chemical structure and CNS effects to existing controlled substances
- Authorizes temporary scheduling (up to 5 years) and permanent scheduling by the Attorney General, with HHS override authority for substances lacking abuse potential
- Imposes penalties of up to 20 years imprisonment and M fines, with enhanced penalties for repeat offenders and cases involving death or serious bodily injury
- Requires IUPAC nomenclature labeling for imported/exported Schedule A substances and establishes registration requirements for legitimate importers
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
Creates a new Schedule A under the Controlled Substances Act to permanently classify and penalize synthetic drug analogues that are imported into the United States with chemical structures and effects substantially similar to existing controlled substances.
Key Policy Areas
Drug Enforcement, Criminal Justice, Import/Export Regulation, Public Health
Primary Purpose
Creates a new Schedule A under the Controlled Substances Act to permanently classify and penalize synthetic drug analogues that are imported into the United States with chemical structures and effects substantially similar to existing controlled substances.
Policy Domains
SIMSA Act of 2025 - Stop the Importation and Manufacturing of Synthetic Analogues
Identified Gains
- Law enforcement agencies (DEA, CBP)
- General public / public health
- Legitimate pharmaceutical researchers (through carve-outs)
Identified Costs
- Illicit synthetic drug importers and manufacturers
- Chemical importers of Schedule A substances
- Pharmaceutical and academic researchers
Sponsors
Legislative Progress
IntroducedMr. Grassley (for himself, Ms. Hassan, Ms. Ernst, Mrs. Shaheen, …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Clinical trial sponsors with active INDs, Existing Schedule I/II registered importers/exporters, Importers and exporters of Schedule A chemical substances
Positive-direction: Clinical trial sponsors with active INDs, Existing Schedule I/II registered importers/exporters, Pharmaceutical companies with FDA-approved products
Negative-direction: Importers and exporters of Schedule A chemical substances, Importers and exporters of controlled substances, Legitimate importers/exporters of Schedule A substances for research and industry
Drug Enforcement Administration, Federal courts, Federal courts and prison system
Positive-direction: Law enforcement agencies
Negative-direction: Drug Enforcement Administration, Federal courts, Federal courts and prison system
Illicit synthetic drug importers and manufacturers, Persons importing, manufacturing, or distributing Schedule A substances
Academic and pharmaceutical researchers, Researchers already registered for Schedule I/II substances
Positive-direction: Researchers already registered for Schedule I/II substances
Negative-direction: Academic and pharmaceutical researchers
Individuals convicted of Schedule A offenses whose substances are later rescheduled
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "secretary"
- → Secretary of Health and Human Services
- "attorney_general"
- → Attorney General of the United States (DOJ/DEA)
- "comptroller_general"
- → Not applicable
Key Definitions
Terms defined in this bill
An offense involving a schedule A substance for which the penalty was established under section 4 or 5 of this Act.
A drug or substance that (i) is or has been imported, or is offered for import, into the United States; (ii) has a chemical structure substantially similar to a controlled substance in schedule I-V AND an actual or predicted stimulant, depressant, or hallucinogenic effect on the CNS substantially similar to or greater than that of a schedule I-V controlled substance; and (iii) is not listed in any other schedule.
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology